COMP <GO>
PGEN vs PHVS // EV/EBITDA & P/E VALUATION
Precigen Inc. (NASDAQ) VS. Pharvaris N.V. (NASDAQ) • 15-METRIC TALLY: PGEN 1
— PHVS 1
■ METRIC PARITY
LAST: $6.64 (+9.21%) • MKT CAP: $2.38B
valuation
—
LAST: $33.58 (+2.32%) • MKT CAP: $2.34B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PGEN VS. PHVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PGEN | PHVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.78% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 146.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.3 | 59.6 | -9.29 | PHVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.38B | $2.34B | $38.0M | PGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PGEN REV | PHVS REV | PGEN GROSS % | PHVS GROSS % | PGEN FCF | PHVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.7M | — | — | — | -$89.8M | — |
| FY 2024 | $3.9M | — | — | — | -$76.8M | — |
| FY 2023 | $6.2M | — | — | — | -$66.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PGEN // BETA —
PHVS // BETA —